Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors
暂无分享,去创建一个
[1] Rolf Rossaint,et al. Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding , 2006, Critical care.
[2] G. Kenet,et al. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven®) , 2003, Journal of thrombosis and haemostasis : JTH.
[3] M. Morfini,et al. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation , 2003, British journal of haematology.
[4] J. Meer,et al. Erratum: Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors (vol 8, pg 649, 2002) , 2002 .
[5] T. Lambert,et al. Myocardial Infarction Occurring in a Case of Acquired Haemophilia During the Treatment Course with Recombinant Activated Factor VII , 2002, Thrombosis and Haemostasis.
[6] J. van der Meer,et al. Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[7] O. Smith. Recombinant Factor VIIa in the Management of Surgery and Acute Bleeding Episodes in Children with Haemophilia and High-Responding Inhibitors , 2002, Pathophysiology of Haemostasis and Thrombosis.
[8] H. Ehrlich,et al. Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse events , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[9] E. Erhardtsen,et al. Potential role for rFVIIa in transfusion medicine , 2002, Transfusion.
[10] P. D. de Groot,et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. , 2002, Blood.
[11] H. Roberts. Recombinant factor VIIa (Novoseven) and the safety of treatment. , 2001, Seminars in hematology.
[12] A. Shapiro. Inhibitor treatment: state of the art. , 2001, Seminars in hematology.
[13] M. Morfini,et al. Relationship between Factor VII Activity and Clinical Efficacy of Recombinant Factor VIIa Given by Continuous Infusion to Patients with Factor VIII Inhibitors , 2001, Thrombosis and Haemostasis.
[14] P. Collins,et al. Elective Surgery on Factor VIII Inhibitor Patients Using Continuous Infusion of Recombinant Activated Factor VII , 2001, Thrombosis and Haemostasis.
[15] C. Quinn,et al. Catheter-related deep venous thrombosis in children with hemophilia. , 2001, Blood.
[16] H. Roberts,et al. Rationale for the use of high dose rFVIIa in a high‐titre inhibitor patient with haemophilia B during major orthopaedic procedures , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.
[17] H. Büller,et al. Ability of Recombinant Factor VIIa to Generate Thrombin During Inhibition of Tissue Factor in Human Subjects , 2001, Circulation.
[18] U. Hedner. Use of High Dose Factor Vila in Hemophilia Patients , 2001 .
[19] U. Hedner. Use of high dose factor VIIa in hemophilia patients. , 2001, Advances in experimental medicine and biology.
[20] Quintana,et al. Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.
[21] G. Mostarda,et al. The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications. , 2000, Thrombosis research.
[22] E. Oger. Incidence of Venous Thromboembolism: A Community-based Study in Western France , 2000, Thrombosis and Haemostasis.
[23] L. Aledort. Recombinant factor VIIa is a pan-hemostatic agent? , 2000, Thrombosis and haemostasis.
[24] A. Street,et al. Experience with continuous infusion of recombinant activated factor VII in the Asia‐Pacific region , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[25] G. Kenet,et al. Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VII , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[26] F. Blei,et al. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[27] J. Lusher. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[28] Jørgensen,et al. Controlling acute bleeding episodes with recombinant factor VIIa in Haemophiliacs with inhibitor: continuous infusion and bolus injection , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.
[29] Allan,et al. Thrombosis in a duplicated superficial femoral vein in a patient with haemophilia A , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.
[30] C. Négrier,et al. The Treatment of Bleeding in Hemophilic Patients with Inhibitors with Recombinant Factor VIIa , 2000, Seminars in thrombosis and hemostasis.
[31] S. Schulman. Continuous Infusion of Recombinant Factor VIIa in Hemophilic Patients with Inhibitors: Safety, Monitoring, and Cost Effectiveness , 2000, Seminars in thrombosis and hemostasis.
[32] E. Erhardtsen. Pharmacokinetics of Recombinant Activated Factor VII (rFVIIa) , 2000, Seminars in thrombosis and hemostasis.
[33] J. Ingerslev. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. , 2000, Seminars in thrombosis and hemostasis.
[34] A D Shapiro,et al. Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors. , 2000, Seminars in thrombosis and hemostasis.
[35] J. Vermylen,et al. Acute Myocardial Infarction Following Administration of Recombinant Activated Factor VII (Novo Seven) in a Patient with Haemophilia A and Inhibitor , 1999, Thrombosis and Haemostasis.
[36] M. Köhler. Thrombogenicity of prothrombin complex concentrates. , 1999, Thrombosis research.
[37] U. Hedner. Treatment of Patients with Factor VIII and Factor IX Inhibitors with Special Focus on the Use of Recombinant Factor VIIa , 1999, Thrombosis and Haemostasis.
[38] C. Francis,et al. Structural Studies of Fibrinolysis by Electron and Light Microscopy , 1999, Thrombosis and Haemostasis.
[39] D. Green,et al. Complications associated with the treatment of haemophiliacs with inhibitors , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.
[40] W. Muntean,et al. Recombinant Factor VIIa Does not Induce Hypercoagulability In Vitro , 1999, Thrombosis and Haemostasis.
[41] E. Santagostino,et al. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention , 1999, British journal of haematology.
[42] J. Gill,et al. Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors , 1998, Thrombosis and Haemostasis.
[43] M. Levi,et al. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium. , 1998, The Netherlands journal of medicine.
[44] J. Vermylen,et al. Optimal care of inhibitor patients during surgery , 1998, European journal of haematology. Supplementum.
[45] Shapiro,et al. A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors , 1998 .
[46] A D Shapiro,et al. Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery , 1998, Thrombosis and Haemostasis.
[47] J. Montoro,et al. Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high‐titre inhibitor , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.
[48] C. Kessler,et al. Safety, efficacy and lessons from continuous infusion with rFVIIa , 1998 .
[49] J. Ingerslev,et al. Clinical use of recombinant FVIIa (rFVIIa). , 1998, Transfusion science.
[50] W M O'Fallon,et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. , 1998, Archives of internal medicine.
[51] C. Bonde,et al. Continuous infusion of recombinant activated factor VII: stability in infusion pump systems. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[52] H. Roberts,et al. Clinical experience with activated factor VII: focus on safety aspects. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[53] U. Fredberg,et al. Home treatment with recombinant activated factor VII: results from one centre. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[54] J. Lusher,et al. Clinical experience with recombinant factor VIIa. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[55] M. Morfini,et al. Experiences with continuous infusion of recombinant activated factor VII. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[56] P. Mannucci,et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.
[57] K. Hassell,et al. Altered hemostasis in pulmonary hypertension. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[58] S. Schulman. Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group. , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.
[59] C. Négrier,et al. The Treatment of Bleeding in Acquired Haemophilia with Recombinant Factor VIIa: A Multicentre Study , 1997, Thrombosis and Haemostasis.
[60] J. Oliver,et al. Platelet activity of high‐dose factor VIIa is independent of tissue factor , 1997, British journal of haematology.
[61] J. Fox. Platelet activation: new aspects. , 1996, Haemostasis.
[62] S. Schulman,et al. Feasibility of Using Recombinant Factor VIIa in Continuous Infusion , 1996, Thrombosis and Haemostasis.
[63] M. Hoffman,et al. Variability in platelet procoagulant activity in healthy volunteers. , 1996, Thrombosis research.
[64] U. Hedner. Dosing and monitoring NovoSeven treatment. , 1996, Haemostasis.
[65] U. Hedner,et al. Clinical update on the use of recombinant factor VII. , 1995, Advances in experimental medicine and biology.
[66] K. Carlsson,et al. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. , 1994, Thrombosis research.
[67] W. T. Sawyer,et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa , 1994, Clinical pharmacology and therapeutics.
[68] S. Rapaport,et al. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. , 1993, Blood.
[69] M. Poon,et al. Deep venous thrombosis in hemophilia A. , 1992, The American journal of medicine.
[70] S. Rapaport,et al. Initiation and regulation of tissue factor-dependent blood coagulation. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.
[71] E. Santagostino,et al. Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody. , 1991, Haemostasis.
[72] C. W. Rettenmier,et al. Direct stimulation of cells expressing receptors for macrophage colony-stimulating factor (CSF-1) by a plasma membrane-bound precursor of human CSF-1. , 1990, Blood.
[73] M. Blombäck,et al. SUCCESSFUL USE OF RECOMBINANT FACTOR VIIa IN PATIENT WITH SEVERE HAEMOPHILIA A DURING SYNOVECTOMY , 1988, The Lancet.
[74] L. Goodnough,et al. Thrombosis or Myocardial Infarction in Congenital Clotting Factor Abnormalities and Chronic Thrombocytopenias: A Report of 21 Patients and a Review of 50 Previously Reported Cases , 1983, Medicine.